Skip to Main Content

Paper Details

Localized ablative immunotherapy drives de novo CD8<sup>+</sup> T-cell responses to poorly immunogenic tumors.
J Immunother Cancer
2
2022
B16, B16-F10 melanoma tumors, B16-F10 tumors, CD8, CD8<, CD8<sup>+</sup>, CD8<sup>+</sup> T-cell, Mice, N-dihydrogalactochitosan, T cells, T-, T-cell, Tumor, immunogenic tumors, metastatic tumors, tumor, tumors
Author NameAffiliation
Saghar KaabinejadianThe University of Oklahoma Health Sciences Center
Mark M DavisStanford University School of Medicine
William H HildebrandThe University of Oklahoma Health Sciences Center
  • 1 - 3

Datasets

Release 1.2